← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Montalbano John S.
Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001834423
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 3
- Purchases · 24M
- 5
- Average purchase
- $116.4K
- Median purchase
- $110.3K
- Gross purchase value
- $582.1K
Companies: AbCellera Biologics Inc.
5 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-08-18 | AbCellera Biologics Inc. | ABCL | Director | $110.3K | Open filing |
| 2026-05-18 | AbCellera Biologics Inc. | ABCL | Director | $95.4K | Open filing |
| 2025-11-26 | AbCellera Biologics Inc. | ABCL | Director | $178.5K | Open filing |
| 2025-03-10 | AbCellera Biologics Inc. | ABCL | Director | $57.5K | Open filing |
| 2025-03-07 | AbCellera Biologics Inc. | ABCL | Director | $140.4K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 5Developing | 100.0% (5/5) | 80.0% (4/5) | +12.6% | +12.5% | -0.4% |
| 20D | 5Developing | 100.0% (5/5) | 80.0% (4/5) | +2.9% | +5.7% | -3.5% |
| 60D | 4Small Sample | 100.0% (4/4) | 50.0% (2/4) | -0.6% | +35.5% | -14.6% |
| 120D | 3Small Sample | 100.0% (3/3) | 100.0% (3/3) | +71.2% | +58.9% | +31.3% |
Research patterns
- First purchase in 12M
- 0/4
- Large purchase ≥ $100k
- 3/5
- Cluster buying · 15D
- 1/5
- Buying the dip
- 4/5
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.